Century Therapeutics, Inc. · NASDAQ:IPSC
Century Therapeutics — Investor Presentation (November 2025)
34 slides from Century Therapeutics's investor presentation, Nov 13, 2025
Slide 1: Advancing Pipeline of Transformative Cell Therapies
Advancing Pipeline of Transformative Cell Therapies Corporate Deck – November 2025
Slide 2: Forward-looking statements
2 Forward - looking statements This presentation contains forward - looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historical f
Slide 3: Century Therapeutics Today
Cell Foundry and Allo - Evasion Technology High Impact Programs Focused on Execution Century Therapeutics Today © 2025 3 Cell foundry generates fully functional cells at scale • Key developmental insights allow directed differentiation of cells that function like primary cells, such as beta Islet ce
Slide 4: Century pipeline spans cell types and targets in autoimmune disease and cancer
4 Clinical IND - enabling Research Indications Targets Product Phase 3 Phase 2 Phase 1 B - cell - mediated autoimmune diseases CD19 CNTY - 101 iNK (Allo - Evasion 1.0) B - cell - mediated autoimmune diseases CD19 CNTY - 308 αβ iT (Allo - Evasion 5.0) Type 1 Diabetes Beta Islet Transplantation CNTY -
Slide 5: Century Therapeutics
CENTURY THERAPEUTICS
Slide 6: Century is a leader in immune evasion engineering
6 Continued evolution to enhance holistic protection from major immunity pathways Century is a leader in immune evasion engineering Allo - Evasion 1.0 Deletion of HLA - I Deletion of HLA - II Insertion of HLA - E Protection from: Native T - cells Native NK - cells Humoral immunity CNTY - 101 CNTY -
Slide 7: Initial clinical proof-of-concept established with Allo-Evasion 1.0
7 Infusion LDC • S imilar PK profile observed for each CNTY - 101 infusion within a cycle despite evident patient immune recovery • PK profile is comparable between cycles with and without LDC* Initial clinical proof - of - concept established with Allo - Evasion 1.0 Similar exposure of CNTY - 101 i
Slide 8: Allo-Evasion 5.0: CD300a TASR ligand protection from host NK cells
8 Allo - Evasion TM 5.0: The CD300a TASR ligand has been shown to provide broad protection from host NK cells Male Female <50 >50 Gender Age Ethni- city CMV Caucasian Other African American Hispanic Negative Positive N = 45 PBMC Donors 0.01 0.1 10 0.01 0.1 1 0 25 50 75 100 0 E:T Ratio T Cell Surviva
Slide 9: Allo-Evasion 5.0: IgG degrading enzyme protects from humoral immunity
9 Immunoglobulin degrading protease As a result, Century’s T cells have been shown to be protected from rejection in preclinical CDC, ADCC and ADCP assays Century T cells have been shown to stably express IDP, an enzyme that cleaves off IgGs below the hinge, releasing the Fc fragment Allo - Evasion
Slide 10: Type 1 Diabetes Program
Type 1 Diabetes Program
Slide 11: Significant unmet need in Type 1 Diabetes
11 Significant unmet need in Type 1 Diabetes (T1D) Despite insulin therapy, people living with T1D face a high risk of life - limiting complications ~9 million people worldwide living with T1D 1 Lifetime economic burden of T1D (US) estimated at~$813 billion 2 T1D is associated with serious comorbidi
Slide 12: Beta Islet cell transplantation provides potentially curative therapy in T1D
12 Beta Islet cell transplantation provides potentially curative therapy in T1D In T1D, beta cells are destroyed Healthy islet beta cells produce insulin (green) In T1D, beta cells are destroyed In T1D, beta cells can be replaced Current approaches have limitations • Major complications in all allog
Slide 13: CNTY-813: Century's Beta Islets with Allo-Evasion 5.0
13 CNTY - 813: Century’s Beta Islets with Allo - Evasion 5.0 Uniquely positioned to potentially deliver a successful T1D cell replacement therapy • Glucose control in patients is important for resolving disease and reducing consequences of uncontrolled glucose • Immune suppression has significant lo
Slide 14: Scalable generation of Beta Islets with Allo-Evasion 5.0
14 A fully scalable, bioreactor - enabled differentiation process yields mature, functional beta Islets from engineered iPSCs iPSCs are engineered with Century’s Allo - Evasion 5.0 to protect cells from immune rejection In vitro and in vivo data support potential to provide functional cure without s
Slide 15: Beta Islets are >99% endocrine and highly potent
15 CNTY - 813 Beta Islets are >99% endocrine and highly potent % Endocrine Cells % Beta Cells CHGA Count NKX6.1 INS iPSC-Beta Islets Primary Islets 0 10000 20000 30000 40000 u I U I n s u l i n / 1 E 6 C e l l s 2mM Glucose 20mM Glucose Purity Potency Glucose - Stimulated Insulin Secretion Stimulati
Slide 16: Beta Islets rapidly restored normoglycemia in STZ-rendered T1D mice
16 CNTY - 813 Beta I slets rapidly r estored normoglycemia in STZ - rendered T1D mice Not for further distribution Century Beta Islets Persisted and Controlled Glucose for >3 Months Non - Fasted Blood Glucose Unedited Beta Islets Allo - Evasion 5.0 Beta Islets 0 30 60 90 120 0 100 200 300 400 500 60
Slide 17: Allo-Evasion 5.0 protects Beta Islets
17 Allo - Evasion 5.0 protects CNTY - 813 Beta Islets ADCC Assay Protection of Beta Islets • NK protection • ADCC protection Allo - Evasion 5.0 on Beta Islets • Elimination of HLA - I and II expression • Confirmed expression of Transgenes Count Normalized to Mode HLA Class I HLA Class II IdeS CD300a
Slide 18: Scalable manufacturing of cryopreserved Beta Islets
18 Scalable manufacturing of cryopreserved Beta Islets Suspension - Based iPSC Differentiation to Cryopreserved Beta Islets Permit Scalable Clinical Manufacturing Scalable iPSC Differentiation Platform Cryopreserved Century Beta Islets Single Dose Clinical Administration 3 - 80L+ PBS (or Stirred Tan
Slide 19: Autoimmune Disease Programs
Autoimmune Disease Programs
Slide 20: Addressing significant unmet need in autoimmunity with allogeneic CAR iT and CAR iNK cells
20 Addressing significant unmet need in autoimmunity with allogeneic CAR iT and CAR iNK cells • Limited but encouraging POC data 2 with CAR - NK therapy support continued development in autoimmune disease • CARAMEL IST with CNTY - 101 currently enrolling patients across four indications • Autologous
Slide 21: CNTY-308 CD4+/CD8+ αβ iT-cell with Allo-Evasion 5.0
CNTY - 308 CD4+/CD8+ αβ iT - cell with Allo - Evasion 5.0
Slide 22: CNTY-308 is an iPSC-derived CD19-targeted CAR-iT
22 CNTY - 308 is an iPSC - derived CD19 - targeted CAR - iT intended for B - cell - mediated disease CNTY - 308 CD4+/CD8+ αβ iT - cell • CD19 - targeted CAR to target B - cells for cytotoxic depletion – 4 - 1BB and CD3z co - stim domain to stimulate expansion on target engagement • Allo - Evasion 5.
Slide 23: CNTY-308 and primary CAR-T function
23 CNTY - 308 1’ CAR - T Function ~2,000 ~3,000 IL - 2 secretion (pg/mL) No No Requires exogenous IL - 2/IL - 15 >10 >10 Repeat killing (rounds) 32 32 Persistence in blood (days) Yes Yes Tumor control after rechallenge ( in vivo) CNTY – 308 and 1’ CAR - T • Self - supports with own target - mediated
Slide 24: Tunable generation of CD4+ and CD8+ αβ T cells without TCR stimulation
24 Tunable generation of CD4+ and CD8+ αβT cells without TCR - stimulation Ending Viability Expansion from iPSCs ( - fold) Stage 90% 3 1 48% 54,000 2 80% 860,000 3+4 77% CD8+/CD4 - CD8+ skewing CD4+ skewing Stage 3 Stage 2: CD4+CD8+ DP T cells CD8 CD4 CD8 CD4 CD8 CD4 80% CD8 - /CD4+ https://www.cent
Slide 25: Effective T cell therapies require three key in vitro cell functions
25 We believe e ffective T cell therapies require the generation of iPSC - CAR - T cells with three key in vitro cell functions Century’s iPSC - derived CAR - αβT cells display the functional characteristics of adult primary T cells: In vitro activity Therapeutic efficacy requires Cytotoxicity: Effe
Slide 26: Preclinical studies: iPSC-CAR-T cells controlled tumors and persisted
26 In preclinical animal studies, Century iPSC - CAR - T cells controlled tumors, persisted for ≥1 month, and retained cytotoxic capacity upon rechallenge In vivo experimental details • Disseminated Nalm6 model (1e5 cells infused) • Effectors added 3 days post - tumor infusion • 1’ CAR - T dose: 5e6
Slide 27: CNTY-101 CAR-iNK cell therapy with Allo-Evasion
CNTY - 101 CAR - iNK cell therapy with Allo - Evasion
Slide 28: CNTY-101 clinical program progressing in CARAMEL Phase 1/2 IST
28 CNTY - 101 clinical program progressing in CARAMEL Phase 1/2 IST Key Inclusion: • Participants with moderate to severe SLE , LN, IIM, or dcSSc with treatment - resistant and active disease, after 2+ standard immunosuppressive therapies Key Endpoints: • Key endpoints: Safety and tolerability, dise
Slide 29: Data in r/r NHL patients supports CNTY-101 in autoimmune diseases
29 Data in r/r NHL patients supports the application of CNTY - 101 in autoimmune diseases Rapid and effective depletion of circulating B - cells observed in the first cycle CNTY - 101 treatment demonstrated deep B - cell depletion and was associated with naive non - class switched profile of re - em
Slide 30: CNTY-101 cells detected in lymph node tumor biopsies
30 CNTY - 101 cells were detected in lymph node tumor biopsies early post - treatment in Dose Level 3B and 4B in ELiPSE - 1 CAR TNFA IFNG CAR TNFA IFNG CAR CAR Scale bar 10µm CNTY - 101 iNK cells traffic to lymph nodes, observed more frequently at higher doses CNTY - 101 trafficking observed in 3 ou
Slide 31: Century Therapeutics
CENTURY THERAPEUTICS
Slide 32: Century platform and in-house manufacturing
32 Century platform and in - house manufacturing: Pathway to scalable, profitable cell therapy Established in - house manufacturing from development to launch Quality product at disruptive scale and cost of goods • Built - for - purpose 53,000 ft 2 cGMP facility • Key leaders each with 1 – 2 decades
Slide 33: Century Therapeutics Today
Cell Foundry and Allo - Evasion Technology High Impact Programs Focused on Execution Century Therapeutics Today © 2025 33 Cell foundry generates fully functional cells at scale • Key developmental insights allow directed differentiation of cells that function like primary cells, such as beta Islet c
Slide 34: Century Therapeutics
CENTURY THERAPEUTICS
Century Therapeutics — Investor Presentation (November 2025) on 6ix